Skip to main content
Clinical Trials/CTRI/2026/01/101806
CTRI/2026/01/101806Not yet recruitingPhase 1

Effectiveness Of Tellurium Metallicum In LM Potencies For Management Of Tinea Corporis Among Patients Aged 20 To 50 Years By Using TCS: A Prospective Single Arm Study

Parul Institute of Homoeopathy and Research1 site in 1 country32 target enrollmentStarted: March 2, 2026Last updated:

Trial Snapshot

Phase
Phase 1
Status
Not yet recruiting
Sponsor
Enrollment
32
Locations
1

Study Overview

Brief Summary

Tinea corporis is a common and recurrent superficial fungal infection in India, particularly affecting individuals aged 20–50 years, with growing resistance and adverse effects associated with conventional antifungal therapies. Tellurium metallicum, a well-indicated homoeopathic remedy for ring-shaped, pruritic, and offensive skin lesions, closely corresponds to the clinical presentation of tinea corporis; however, clinical evidence for its effectiveness in LM potencies remains limited. This prospective single-arm study aims to evaluate the effectiveness of Tellurium metallicum in LM potencies for the management of tinea corporis using the Tinea Corporis Score (TCS). A total of 32 clinically diagnosed patients (ICD-10 CM B35.4), aged 20–50 years, will be enrolled through purposive sampling from the OPD and IPD of Parul Institute of Homoeopathy and Research Hospital, Vadodara. Tellurium metallicum will be administered orally in liquid form, starting from LM 0/1 and adjusted according to clinical response, with weekly follow-up for up to 6 weeks. Treatment outcomes will be assessed using TCS, and the collected data will be statistically analyzed to determine the clinical effectiveness of the intervention.

Study Design

Study Type
Interventional
Allocation
Na
Masking
None

Eligibility Criteria

Ages
20.00 Year(s) to 50.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Cases which are clinically diagnosed according to ICD-10 CM, B35.4 criteria.
  • All socio-economic status.
  • Patient who will provide informed consent.

Exclusion Criteria

  • Patient who are taking simultaneously any other treatment for the tinea corporis.
  • Patients with any type of severe systemic illnesses.
  • Pregnant and lactating women.

Investigators

Sponsor
Parul Institute of Homoeopathy and Research
Sponsor Class
Research institution and hospital
Responsible Party
Principal Investigator
Principal Investigator

Ishita Jignesh Khant

Parul Institute of Homoeopathy and Research Hospital

Study Sites (1)

Loading locations...

Similar Trials